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A new analog of EPO was designed by fusing one and two CTPs to the N-terminal and C-terminal ends of EPO (EPO-(CTP)3),
respectively. This analog was expressed and secreted eﬃciently in CHO cells. The in vitro test shows that the activity of EPO-
(CTP)3 in TFI-1 cell proliferation assay is similar to that of EPO-WT and commercial rHEPO. However, in vivo studies indicated
that treatment once a week with EPO-(CTP)3 (15μg/kg) dramatically increased (∼8 folds) haematocrit as it was compared to
rHuEPO. Moreover, it was found that EPO-(CTP)3 is more eﬀective than rHuEPO and Aranesp in increasing reticulocyte number
in mice blood. The detected circulatory half-lives of rHuEPO, Aranesp, and EPO-(CTP)3 following IV injection of 20 IU were 4.4,
10.8, and 13.1 h, respectively. These data established the rational for using this chimera as a long-acting EPO analog in clinics. The
therapeutic eﬃcacy of EPO-CTP analog needs to be established in higher animals and in human clinical trials.
1.Introduction
Erythropoietin (EPO) is a 34-kDa glycoprotein hormone
produced primarily by cells of the per tubular capillary
endothelium of the kidney and regulates red blood cell pro-
duction through stimulation of erythropoiesis [1, 2]. EPO
synthesis in the kidney is increased following reduction in
tissue oxygenation, it binds to speciﬁc receptors on red blood
cell precursors in the bone marrow leading to proliferation,
diﬀerentiation, and to an increase in haematocrit [3]. Bio-
logical responses associated with EPO include activation of
intracellularsignalingmoleculessuchastranscriptionfactors
like signal transducer and activator of transcription (STAT)
proteins leading to cellular growth and diﬀerentiation. EPO
receptor belongs to a family of homodimerization receptors
where dimerization of the receptor is required to trigger the
biological responses associated with EPO [4–7]. Anemia in
patients with chronic kidney disease is due to a number
of factors, the most common of which is abnormally low
erythropoietin levels. Anemia of EPO deﬁciency is recog-
nized in advanced renal failure but not in early renal disease.
Deﬁciency in EPO production results in anemia in humans
and in animal models. EPO is heavily glycosylated with one
O-linked and three N-linked oligosaccharide chains. It was
found that O-linked oligosaccharide chain has no eﬀect on
secretion, receptor binding aﬃnity, and in vitro or in vivo
bioactivity. On the other hand, N-linked oligosaccharide-
chains have no role in in vitro activity, but it is critical for
in vivo bioactivity [8].
The gene encoding human erythropoietin was cloned
in 1985 leading to the production of recombinant human
EPO (rHuEPO) [9, 10]. rHuEPO was used successfully in
treatinganemiaassociatedwithchronickidneydisease.Ithas
also been approved for the treatment of anemia associated
with cancer, HIV infection, and in the surgical setting in
order to reduce blood transfusions [11–13]. One major issue
regarding the clinical use of EPO is its relatively short half-
life in vivo due to its rapid clearance (∼5 hours) from the2 International Journal of Cell Biology
circulation when it is injected intravenously [14]. Thus, the
clinical therapeutic protocols of available stimulating agents
used in the treatment of patients require frequent injections
of EPO. The recommended therapy with rHuEPO is 2-3
times per week by subcutaneous or intravenous injections.
Therefore, it can be anticipated that enhancing the in vivo
half-life of EPO would reduce the number of injections
per week. Previous studies indicated that there is a direct
relationship between the sialic acid-containing carbohydrate
content of the molecule and its serum half-life and in vivo
bioactivity [15–17]. It was shown that fusing the carboxyl-
terminal peptide (CTP) of hCGβ subunit that associated
with four sites of O-linked oligosaccharide chains to the C-
terminal of FSH, TSH, GH, and EPO cDNA did not aﬀect
secretion, receptor binding aﬃnity, and in vitro bioactivity.
Ontheotherhand,theadditionofO-linkedoligosaccharides
to the backbone of the protein signiﬁcantly increased the
half-life and longevity in vivo [18–22]. We hypothesis that
the addition of 12 O-linked oligosaccharide chains to the
backbone of EPO will dramatically increase the longevity
of EPO. Therefore, in the present study, three carboxyl-
terminal peptides (CTP) of hCGβ subunit that each contains
four O-linked oligosaccharide recognition sites was fused to
N-terminal (one) and to the C-terminal (two) of human
EPO coding sequence, respectively. Our results indicate that
ligation of three CTPs to the coding sequence of EPO
dramatically increased both in vivo potency and half-life in
the circulation.
2.MaterialsandMethods
2.1. Materials. Enzymes used in the construction of DNA
vectors and constructs were purchased from New England
BioLabs (Beverly, Mass, USA). Cell culture media and
reagents were obtained from Biological Industries (Beit
Haemek,Israel).RabbitantiseraagainstEPOwerepurchased
from Fitzgerald (Concord, Mass, USA). The eukaryotic
expressionvector(pCI-DHFR,Dihydrofolatereductase)into
which the cDNA encoding for the corresponding hEPO
variants were inserted was purchased from Promega, (San
Luis Obispo, Calif, USA). Commercial human recombinant
EPO (Eprex) was purchased from Janssen-Cilag (North
Ryde, NSW, Australia).
2.2. Crystallography. The interaction between EPO and its
receptor was crystallized as described previously [23] by the
Department of Structural Biology, Weizmann Institute of
Science, Rehovot, Israel.
2.3.ConstructionofChimericGenesandExpressionVectors. A
cassette gene containing the CTP of hCGβ was fused in tan-
dem to the coding sequence of EPO at the N-terminal (one
CTP)andtotheC-terminalend(twoCTPs)(Figure 1).DNA
fragment containing sequences of hEPO-cDNA and coding
sequence of CTP were synthesized by GeneArt (Regensburg,
Germany). The DNA fragments contain the recognition sites
of the restriction enzymes; Xba I (in the N-terminal)a n dNot
I (in the C-terminal). Fragment containing hEPO and CTP
sequences was completely sequenced to ensure that no errors
wereintroducedduringsynthesisandligatedintotheXbaI—
Not I sites at the cloning site of the eukaryotic expression
vector, pCI-DHFR. Similarly, cDNA of human EPO (EPO-
WT) was constructed into pCI-DHFR vector.
2.4. Cell Culture and DNA Transfection. Chinese hamster
ovary (CHO)-DG44 cells, which are DHFR negative, were
used. Cells were cultured in MEM-α medium (Gibco BRL,
USA) supplemented with penicillin (100U/mL), strepto-
mycin (100mg/mL), L-glutamine (2mM), and 10% heat-
inactivated fetal bovine serum at 37◦C in humidiﬁed incu-
bator containing 5% CO2. These cells were transfected with
2μgDNAofplasmidbyusingFuGENE6(Roche,Mannheim,
Germany) according to manufacturer protocol.
Cells were selected for insertion of the plasmid DNA by
growth in culture medium of CD DG44 without hypoxan-
thine and thymidine (HT) (Gibco BRL, USA) supplemented
with 8 mM L-Glutamine (Biological Industries, Beit Haimic,
Israel) and 18mL/L of 10% Pluronic F-68 solution (Gibco
BRL, USA).
2.5. Western Blotting. Samples of condition medium which
were collected from stable clones were electrophorised
on denaturing 15% SDS-polyacrylamide gels as described
before [24]. Gels were allowed to equilibrate for 10min
in 25mM Tris and 192mM glycine in 20% (vol/vol)
methanol. Proteins were transferred to a 0.2μmp o r es i z e
nitrocellulose membrane (Sigma, Saint Louis, Mo, USA)
at 250mA for 3h using a Mini Trans-Blot electrophoresis
cell (Biorad Laboratories, Richmond, CA) according to the
method described in the manual accompanying the unit.
The nitrocellulose membrane was incubated in 5% nonfat
dry milk for 2h at room temperature. The membrane
was incubated with EPO antiserum (1:1000 titers) for
overnightat4◦CfollowedbythreeconsecutivewashesinPBS
containing 0.1%Tween(10min/wash).Then,themembrane
was incubated with secondary antibody conjugated to Horse
Radish Peroxidase (HRP) (Zymed, San Francisco, CA) for
2h at room temperature followed by three washes. Finally,
the nitrocellulose paper was reacted with enhanced chemi-
luminescent substrate (ECL) (Pierce, Rockford, Ill, USA) for
5min, dried with Whatman sheet and exposed to X-ray ﬁlm.
2.6. In Vitro Bioactivity. Bioactivity of EPO variants was
assayed by testing the proliferation dependence of the
human erythroleukemic cell line TF-1 (Kitamura) (DSMZ)
in the presence of EPO and EPO variants [25]. Cultures
were routinely grown at 37◦C, 5% CO2 for 72hrs in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS),10mM Hepes, 1mM sodium pyruvate, 2.5g/L
glucose, 2mM glutamine, and 2ng/mL rhGM-CSF. Before
transferring the cells to 96-well plates, the TF-1 cells were
washed three times with cold PBS and suspended in the
assay medium (1640 medium supplemented with 10% fetal
bovine serum (FBS) but without addition of rHGM-CSF) at
a density of 200,000cells/mL. The assay was performed in
96-well plates containing 50μL of cell suspension per well.International Journal of Cell Biology 3
CTP CTP CTP EPO-cDNA
5- -3
TCCTCTTCC.....CTCCCACAATAA
Ser Ser Ser .... Leu Pro Gln Term
118 119 120 .... 143 144 145
hCGβ-CTP
ATGGGGGTG....GGGGACAGA
Met Gly Val .... Gly Asp Arg
123 .... 190 191 192
EPO-cDNA
Not I Xba I
Figure 1: Construction of EPO-(CTP)3 chimeric gene. The chimeric gene contains the cDNA of human erythropoietin and three hCGβ
carboxyl-terminal peptides that were ligated to the N-terminal (one) and to C-terminal (two) coding sequences.
50μL of assay medium containing 3IU of EPO variants were
then added to the wells of 96-well plates for 72hrs. Cell
viability was measured using MTT reagent kit (Cell Biolabs,
San Diego, CA) according to manufacturer procedures.
2.7. Animals. Male ICR mice were obtained from Charles
River Laboratories, Jerusalem, Israel, and housed in air-
conditioned quarters with a 12h light/dark schedule. Stan-
dard food and water were available ad libitum.I n s t i t u t e
ethical committee approved the in vivo protocols. Animals
were treated with EPO variants as speciﬁed.
2.8. In Vivo Bioassay. Groups of 7 male ICR mice (7-week-
oldmales)wereused.EPO-WT,EPO-(CTP)3,orcommercial
rHuEPO were injected to anesthetized animals as described
in Table 1.
Theanimalswereweighed,andeachreceivedanidentical
amount (5 or 15μg/kg) of EPO variants by IV injections
(0.2mL/animal). The frequency of treatment was either
thrice weekly (days 1, 3, and 5) or once weekly. The level
of haematocrit was determined three times a week and
the experiment was stopped after three weeks. Haematocrit
was determined using blood samples obtained by ﬁlling
two heparinized microhematocrit tubes from the inferior
caval vein under anesthesia. In addition, reticulocyte counts
were conducted since these cells are present in blood for
∼48 hours before developing into mature red blood cells.
Reticulocytes represent an appropriate evaluation for the
acute experimental system employed. Blood was obtained
from each pup by cardiac puncture and placed in EDTA
coated tubes. This was then mixed with brilliant cresyl blue
and incubated for 20min at 37◦C. The blood and stain
were then smeared onto a glass slide and the number of
reticulocytes assessed using a × 100 oil objective lens.
2.9. Metabolic Clearance Rate. The metabolic clearance of
EPO-WT, Aranesp, and EPO-(CTP)3 was determined after
IV injection of 20IU/animal into male ICR mice. At selected
intervals after injection, blood samples were collected and
EPO immunoreactivity was determined by RIA.
2.10. Statistical Analysis. Data were expressed as the mean
± SEM. Statistical analysis of the data were performed
using Student’s t-test and 1-way multivariate analysis of
N-terminal
C-terminal
Figure 2: Model of erythropoietin binding to its receptor. The
diagram showing the complex of EPO bound to the receptor.
Note that the N-terminal and C-terminal of EPO are free and not
involved in the binding site.
variance(ANOVA1)tocalculateP value.P values<0.05were
considered statistically signiﬁcant.
3. Results and Discussion
Chrystallographic studies indicated that the N-terminal and
C-terminal of EPO are not involved in the binding of the
hormone to the receptor (Figure 2).
Therefore, we hypothesized that ligation of CTP to the
N-terminal and to the C-terminal of EPO will not aﬀect
receptor binding aﬃnity and thus bioactivity. Therefore,
three CTPs (one in the N-terminal and two in the C-
terminal) were ligated to the coding sequence of EPO. The
cDNA of human EPO-WT and EPO-(CTP)3 was inserted
into the eukaryotic expression vector, pCI-DHFR, and
transfected into CHO cells. Stable clone expressing human
EPO-WT or EPO-(CTP)3 was selected. Secretion of EPO
was assessed by Western blot analysis under denaturing
conditions using human EPO-speciﬁc antiserum. The EPO-
WT migrated faster than EPO-(CTP)3 (Figure 3).4 International Journal of Cell Biology
Table 1: Comparative 3 week induction of haematocrit by EPO-(CTP)3 and rHuEPO.
Group number Mice/group Treatment Regimen: IV
Compound Dose μg/kg
1
n = 7
Vehicle (control) 0
O n ed o s ep e rw e e k 2 rHuEPO 15μg/kg
3 EPO-(CTP)3 15μg/kg
4 Commercial rHuEPO 5 3 doses per week
EPO-WT EPO (CTP)3
57
37
28
Figure 3: Expression of EPO-WT and EPO-(CTP)3 from trans-
fected CHO cells. Conditioned media from transfected cells were
prepared for SDS/PAGE and proteins were detected by Western blot
as described under “Materials and Methods.”
EPO-(CTP)3 exhibited high molecularweight (∼57kDa)
comparing to EPO-WT (∼36kDa) due to the addition of
84 amino acids and the O-linked oligosaccharides linked to
CTP. These data may indicate that the O-linked glycosylation
recognition site of the C-terminal region is preserved even
though the sequence is fused to diﬀerent proteins. Levels
of EPO-WT and EPO-(CTP)3 were quantities in condition
medium by using a monoclonal antibody-based RIA.
The in vitro biological activity of EPO analogs was
demonstrated by measuring their ability to stimulate the
proliferation of TF-1 cells as described under “Materials
and Methods.” The activity of EPO-(CTP)3 in TF-1 cell
proliferation assay was similar to that of EPO wild-type
(prepared by Modigene Tech) and commercial rHuEPO
(Figure 4).
For further pharmacological evaluation of EPO-(CTP)3,
comparative pharmacodynamic studies of EPO-(CTP)3 and
commercial rHuEPO were performed in male ICR mice
(n = 7/group) using diﬀerent frequencies and dose range
as described in Table 1.T h ein vivo eﬃcacy was obtained by
measuring the mean values of haematocrit percentage in the
blood. The results indicated that EPO-(CTP)3 is signiﬁcantly
(P<0.001) more eﬃcient than rHuEPO when administered
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Figure 4: In vitro biological activity of recombinant hEPO deriva-
tives. Bioactivity of EPO variants was tested by measuring the
proliferation dependence of human erythroleukemicTF-1 cells in
the absence or presence of 3IU of EPO variants. Cell proliferation
was measured using MTT reagent kit.
IV once a week with a dose of 15μg/kg (Figure 5). EPO-
(CTP)3 can successfully increase the haematocrit when
administered once a week with a dose of 15μg/kg (Figure 5).
Once weekly dosing with the same concentration of com-
mercial rHuEPO or EPO-WT was signiﬁcantly (P<0.001)
less eﬃcient than once weekly dosing of EPO-(CTP)3.A n
interestingobservationfromthepresentstudywastheability
of a single injection once a week of EPO-CTP (15μg/kg) to
increase dramatically (∼8 folds) the levels of haematocrit.
Whereas administration of the same total dose of rHuEPO
administered three times a week as 5μg/kg per injection
resulted in signiﬁcantly (P<0.001) lower eﬀect (Figure 5).
Previously, we have shown that single injection once
a week of EPO-CTP, an EPO that contains one CTP at
the carboxyl-terminal end, (15μg/kg) increased the level of
haematocrit,whereasthesameeﬀectwasachievedbyadmin-
istration of the same total dose of rHuEPO administered
three times a week as 5μg/kg per injection [21]. These results
indicated the importance of sustained blood levels, rather
thantotaldoseofEPO.Theseﬁndingsareconsistentwiththe
hypothesis that the ability of a single injection of EPO-CTP
to increase haematocrit results from its increased stability in
the circulation.
Eﬀect of EPO-WT, (EPO-CTP)3, and Aranesp in reticu-
locyte counts is shown in Figure 6. The results indicated that
a single IV injection of 15μg/kg (EPO-CTP)3 dramaticallyInternational Journal of Cell Biology 5
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Figure 5: In vivo bioactivity of recombinant HuEPO derivatives.
ICR mice (n = 7/group) received a single IV injection/week
(15mg/kg) for three weeks of EPO-WT, rHuEPO, or EPO-(CTP)3.
In addition, mice were treated with 5μg/kg of rHuEPO three times
a week for 3 weeks. Control animals were injected IV with saline.
Blood samples were collected three times a week and haematocrit
levels were detected. Each point represents the group average of
haematocrit (%) ± SE. ∗P<0.0.5, ∗∗P<0.01, and ∗∗∗P<0.001.
Table 2: Mean pharmacokinetic parameters following IV admin-
istration of a single dose (20μg/kg) of rHuEPO, EPO-(CTP)3,
and Aranesp in male ICR mice. Parameters were generated for
individual rats and the mean data are presented here.
Parameters rHuEPO EPO-(CTP)3 Aranesp
AUC (hr∗μg/L) 31739 306072 178661
Cmax (μg/L) 10766 16466 13266
Tmax (hr) 0.25 0.25 0.25
T1/2 (α) (hr) 4.4 13.11 10.84
increased reticulocyte number compared to rHuEPO and
to Aranesp. The increased biopotency of the chimera may
reﬂect a change in their in vivo longevity. Therefore, the
circulatory half-lives of the hormones were determined.
EPO-WT, Aranesp, or EPO-(CTP)3 was injected IV into
immature male mice and RIA monitored the plasma half-
lives. The results indicated that EPO-(CTP)3 has the highest
half-life in circulation (Figure 7).
The estimated half-lives of EPO-WT, Aranesp, and EPO-
(CTP)3 are 4.4, 10.8, and 13.1 hours, respectively (Table 2).
These data suggest that the mechanism of EPO clearance is
aﬀected by the presence of CTP. Estimation of area under
the curve (AUC) and the maximal plasma concentration
(Cmax) of EPO-(CTP)3 are higher than that of rHuEPO and
Aranesp. However, the maximal concentration reached in
plasma (Tmax) is similar (Table 2).
Previous studies indicated that the CTP sequence can be
shuttled into diﬀerent proteins and still be an acceptor for
the O-linked oligosaccharides [18–20]. It was postulated that
Days
25
20
15
10
5
0
048 1 2
Aranesp
R
e
t
i
c
u
l
o
c
y
t
e
s
(
c
h
a
n
g
e
(
%
)
)
rHuEPO
∗∗∗
EPO (CTP)3 -
Figure 6: The eﬀect of a single IV injection of EPO variants on
reticulocyte counts in mice. ICR mice (n = 7/group) received a
single IV injection/week for three weeks of rHuEPO, Aranesp, or
EPO-(CTP)3 (15mg/kg). Blood samples were collected after 72h
and reticulocytes were counted. Each point represents the group
average of reticulocyte (%) ± SE. ∗∗∗P<0.001.
the O-linked oligosaccharides add ﬂexibility, hydrophilicity,
and stability to the protein [26]. This may explain the dis-
interference of CTP on the protein conformation and, thus,
on receptor binding and bioactivity in vitro. On the other
hand, it was suggested that the O-linked oligosaccharides
play an important role in preventing plasma clearance and
thus increasing the half-life of the protein in the circulation
[18, 21, 22]. These roles have been postulated since the O-
linked oligosaccharides are ended with sialic acid, which is
negatively charged. Itis known thatnegatively chargedforms
of the hormones are less cleared through the glomerular
ﬁltration [27]. Thus, addition of 12 O-linked oligosaccharide
chains to the backbone of EPO signiﬁcantly decreased renal
clearance; the kidney is the main site of clearance for
glycoprotein hormones and, thus, prolonged its half-life in
the circulation.
Other studies described long acting hyperglycosylated
EPO analog that prepared by addition of N-linked oligosac-
charides to the backbone of the protein. In order to add
N-linked oligosaccharide chains, the DNA sequence of the
cloned human EPO gene was modiﬁed by site-directed
mutagenesis [28]. This analog was 3-fold longer serum
half-life and created in vivo potency comparing to human
recombinant EPO-WT. However, its relative aﬃnity for the
EPO receptor was ∼4-fold lower than that of rHuEPO.
Moreover, changing 5 amino acids in the backbone of
the protein may increase the immunogenicity of the new
derivative.
Addition of CTP to the coding sequence of hormones
FSH, TSH, and GH, do not aﬀect secretion, receptor binding
aﬃnity, or bioactivity in vitro [18–22]. On the other hand,
it was found that ligation of CTP to the coding sequence
signiﬁcantly increases the in vivo potency and half-life of the6 International Journal of Cell Biology
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Figure 7: In vivo half-life of EPO variants. Mice were injected
IV with 20IU of rHuEPO, Aranesp and EPO-(CTP)3 and blood
samples were drawn at the indicated times. Serum levels of EPO
weredeterminedbyRIA.Mean±SEof5determinations.BasalEPO
levels before treatment were unmeasured.
hormone.Moreover,itwasfoundthathormonebearingCTP
is safe for use in human and not immunogenic [29–31].
The present study describes a novel long-acting recom-
binant erythropoietin agonist designed by fusion of three
CTP sequences to the coding sequence of EPO. This did not
interfere with secretion or in vitro bioactivity. In contrast,
addition of CTP sequences signiﬁcantly increased the in
vivo potency and half-life of EPO. These data establish a
rationale for using this chimera as a long-acting EPO analog.
However, the immunogenicity of this analog should be
tested. Human erythropoietin has a wide clinical use in the
treatment of anemia associated with a renal failure, HIV,
and chemotherapy [32–36]. The therapeutic eﬃcacy of this
analog needs to be establishing in higher animals and in
human clinical trials.
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